Curative Biotechnology, Inc. announced a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI), a part of the National Institutes of Health (NIH). Under a Cooperative Research and Development Agreement (CRADA), the National Eye Institute and Curative Biotechnology, Inc. will collaborate to evaluate Curative's proprietary ocular metformin formulation in clinical studies for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 USD | -7.24% | -20.00% | -6.10% |
05-06 | Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. | CI |
1st Jan change | Capi. | |
---|---|---|
-6.10% | 18.07M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.39% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- CUBT Stock
- News Curative Biotechnology, Inc.
- Curative Biotechnology Announces Cooperative Research and Development Agreement with the National Eye Institute